BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-683@pharmaconomics
DTSTAMP:20260707T034117Z
DTSTART;VALUE=DATE:20260327
DTEND;VALUE=DATE:20260328
SUMMARY:VSTM PDUFA — AVMAPKI FAKZYNJA CO-PACK
DESCRIPTION:The FDA's approval decision on AVMAPKI FAKZYNJA CO-PACK for KRAS mutant-type (mt) recurrent Low-Grade Serous Ovarian Cancer (LGSOC) is due Mar 27\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/1526119/000110465926010036/tm265057d1_ex99-1.htm\n\nTrack it: https://www.pharmaconomics.com/e/683
URL:https://www.pharmaconomics.com/e/683
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:VSTM catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR